Malaria: New vaccine candidate shows promise in clinical trials | Medical News Today

CEID Interim Director Dr. David Hamer weighs in on the R21/Matrix-M malaria vaccine candidate:

“Dr. Davidson Hamer, professor of Global Health and Medicine at the Boston University, told Medical News Today, that one of the limitations of the study ‘is that this is a relatively small sample size per group and there were other prevention interventions happening in this community during this time — although this should have been equally spread across all three groups.’

‘It will be important to follow this up with a larger, multi-country study in areas with different levels of malaria transmission, underlying undernutrition of children, and different degrees of implementation of malaria control measures,’ he added.

To further assess the efficacy and safety of the R21 vaccine candidate in a larger sample, the researchers have enrolled 4,800 children for a phase 3 clinical trial.

Read the full article here